Developer docs
API playgroundTry for free, no card

Search company profiles

Ainnocence

Full company profile

uuid0003ig7

Namestring
Ainnocence
Legal namestring
Ainnocence Inc.
Websiteurl
ainnocence.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Ainnocence is a California-based AI-native biotech founded in 2021 that develops sequence-based AI platforms for drug discovery and materials design. The company's core technology is a proprietary computationally efficient foundation model using block-circulant FFT layers and κ→1 Hessian conditioning, achieving 3.8× parameter reduction while powering three product pillars: SentinusAI® (biologics — antibodies, proteins, peptides, RNA, cell therapy, and synthetic biology), CarbonAI® (chemistry — small molecules, PROTACs, natural products, formulation, and cosmetic actives), and MaterialAI™ (advanced materials for semiconductors, alloys, and aerospace). The platform screens 10 billion+ compounds per day on a single GPU without requiring experimental 3D protein structures, claiming 10–60% wet-lab hit rates versus the 0.1–1% industry baseline and 80% cost reduction versus traditional high-throughput screening. Validation comes from peer-reviewed Nature Scientific Reports publication (2025), an ACS/C&EN white paper (2025), and 20+ PCT patents.

The company operates a multi-modal revenue model: (1) platform subscription licensing of its AI engines to pharma, biotech, CROs, cosmetics, and materials companies; (2) fee-for-service design campaigns where Ainnocence delivers wet-lab-ready lead candidates on a per-program or milestone basis; (3) co-development and strategic partnerships (exemplified by the January 2026 Phase Advance collaboration) with milestone payments and potential downstream royalties; and (4) B2B SaaS for cosmetics and materials R&D. Go-to-market combines enterprise field sales with consulting-style discovery, a self-service portal at app.ainnocence.com for mid-market adoption, scientific publication-driven inbound, and the JP Morgan Healthcare Conference as a key deal-closing venue. The company reports 1–10 employees across Mountain View HQ and Boston, with no disclosed funding rounds to date, and is led by Founder/CEO Dr. Lurong Pan (ex-Bill & Melinda Gates Foundation Senior Investigator).

Short descriptiontext

Ainnocence is an AI-native biotech developing sequence-based foundation models for biologics, small-molecule, and materials discovery, serving pharma, biotech, cosmetics, and semiconductor customers via platform licensing, fee-for-service, and co-development partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, therapeutic antibody design, small molecule discovery, materials science AI, computational biology
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery Platform
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Platform Licensing
TypeSubscription Recurring
Description

Ainnocence licenses its AI platforms (SentinusAI, CarbonAI, MaterialAI, etc.) to pharmaceutical, biotech, and materials companies. This is the primary revenue model, targeting enterprise customers through annual or multi-year subscription contracts.

ainnocence.com
2Fee-for-Service (FFS) Design Campaigns
TypeProfessional Services
Description

Per-project or per-campaign design engagements where Ainnocence applies its AI platforms to specific therapeutic programs, delivering wet-lab-ready lead candidates. Charged on a per-program or milestone basis.

ainnocence.com
3Co-Development / Strategic Partnerships
TypeLicensing Royalties
Description

Joint development arrangements with pharmaceutical partners where Ainnocence contributes AI-driven drug design capabilities, often tied to milestone payments and downstream royalties. The Phase Advance collaboration exemplifies this model.

ainnocence.com
4B2B SaaS for Beauty and Materials R&D
TypeSubscription Recurring
Description

Platform subscriptions and usage-based access for cosmetic brands and materials companies (e.g., CosmeticAI for beauty R&D, MaterialAI for semiconductor and chemical companies), uncorrelated to pharmaceutical revenue streams.

ainnocence.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Pricing details1 tier
1Platform subscription and per-program pricing models available via app portal
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based / Not publicly disclosed

ainnocence.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 11 records shown
1SentinusAI
Description

AI platform for de novo protein design and antibody engineering using deep learning to predict and optimize protein structures.

ainnocence.com
+10 more records
Core offering1 text field

Ainnocence develops three AI-driven platform pillars for therapeutic and materials R&D: SentinusAI for biologics (antibodies, proteins, peptides, RNA, cell therapy, synthetic biology), CarbonAI for chemistry (de novo small molecules, natural products, synthesis planning, formulation, cosmetic actives), and MaterialAI for advanced materials (alloys, semiconductors, crystals). All three are powered by a proprietary computationally efficient foundation model using block-circulant FFT layers and operate on sequence representations rather than requiring experimental 3D protein structures. The platforms are licensed to pharma, biotech, CROs, cosmetics, and semiconductor customers via subscription, fee-for-service design campaigns, and co-development partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Up to 80% reduction in early drug discovery cost and time
+7 more records
Product overview1 text field

Ainnocence operates a platform-plus-modules architecture organized around three core AI pillars: biologics, chemistry, and materials. The flagship biologics platform SentinusAI® (protein/antibody design engine) includes five integrated modules: Antibody Studio, Peptide Studio, RNA Studio, Cell Studio, and SynBio Studio. The chemistry platform CarbonAI® (small molecule design engine) integrates SynMagic™ for retrosynthesis planning alongside modules for natural products, synthesis, formulation, and cosmetic actives. MaterialAI™ provides a separate AI materials discovery pillar. All three platforms share a proprietary computationally efficient foundation model as the core technology engine. Additional products include SenseAI® (RNA therapeutics), BioSynthAI® (synthetic biology), FormulaAI® (formulation optimization), NatmolAI® (natural products), CellulaAI® (cell therapy), PeptideAI® (peptide design), and CosmeticAI® (cosmetic ingredients). The company was founded in 2021 in California and serves customers across big pharma, biotech, CROs, cosmetics, semiconductors, and chemicals sectors.

Product and service5 records
1SentinusAI®
CategoryBiologics AI Platform
Description

End-to-end AI platform for therapeutic antibody and biologics discovery operating on protein and DNA sequence data. Built on a proprietary up-to-1-billion-parameter transformer-based protein foundation model trained on 53.5M+ sequences and 4.04M+ antibody screening datapoints. Achieves 85.7% affinity maturation success across 42 antibody projects and 10–60% wet-lab hit rates versus an industry baseline of 0.1–1%. Includes Product Modules: Antibody Studio (IgG, Fab, scFv, VHH design and affinity maturation), Peptide Studio (cyclic, stapled, GLP-1 analogs), RNA Studio (mRNA codon optimization, siRNA design), Cell Studio (cell line engineering, genome screening), and SynBio Studio (gene design, strain optimization). Sold via platform subscription, fee-for-service design campaigns, and co-development licensing to biopharma, biotech, peptide, RNA therapeutics, and cell therapy customers.

2CarbonAI®
CategoryChemistry AI Platform
Description

End-to-end molecular chemistry platform for de novo small-molecule and PROTAC drug design and discovery, trained on a 2.02B-entry chemical foundation model with 600K molecular generation, 564K target binding, and 267,872 ADMET datapoints. Capabilities include virtual screening of up to 10 billion compounds within hours, scaffold hopping, multi-objective optimization, and the SynMagic retrosynthesis planning module with 95% synthesis success rate. Includes Product Modules: Molecule Design, Natural Products (800K+ NP database and TCM modernization), Synthesis Planner, Formulation Engine, and Cosmetic Actives. Sold to pharma, biotech, CROs, specialty chemicals, and cosmetics customers via subscription licensing and fee-for-service design campaigns.

3MaterialAI™
CategoryMaterials AI Platform
Description

AI-based platform for advanced materials discovery and optimization, operating on 9.04M material entries across six categories including 1.4M experimental crystals, 5.475M DFT-relaxed inorganics, 1.3M catalyst surfaces, 33K superconductor entries, 700K organic/organometallic entries, and 132K ML benchmark splits. Capabilities include alloy and composite design (high-performance alloys, functional materials, nanomaterials), semiconductor materials (polyimide FCCL, TPU elastomers, process optimization), and crystal structure prediction (stability, phase prediction, process routes). Sold to semiconductor manufacturers, chemical companies (BASF, Dow, DuPont), battery, and aerospace customers via platform licensing and project-based consulting, with revenue uncorrelated to the pharmaceutical pillars.

4Fee-for-Service Design Campaigns
CategoryProfessional Services
Description

Per-program or per-campaign design engagements in which Ainnocence applies SentinusAI, CarbonAI, MaterialAI, and related modules to specific therapeutic or materials programs, delivering wet-lab-ready lead candidates. Billed on a per-program or per-milestone basis with milestones tied to design, screening, and validation outcomes. Targets pharma, biotech, CRO, and specialty chemical customers that need expert execution on a specific program rather than a platform license.

5Co-Development Strategic Partnerships
CategoryStrategic Partnerships
Description

Joint development arrangements with pharmaceutical and clinical partners in which Ainnocence contributes AI-driven drug design capabilities and the partner contributes development, clinical, or commercial capabilities. Structured with milestone payments and downstream royalties. The Phase Advance collaboration is the flagship example, integrating Ainnocence's AI-driven drug design with predictive clinical outcome modeling to reduce development timelines by over 50%.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Phase Advance
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-29
Description

Industry-first AI collaboration integrating Ainnocence's AI-driven drug design capabilities with Phase Advance's predictive clinical outcome modeling. The partnership aims to reduce drug development timelines by over 50% and lower clinical trial failure rates. Addresses critical failure points where approximately 95% of drug candidates fail before preclinical research and 98% fail Phase 1 trials. The collaboration was finalized at the JP Morgan Healthcare Conference and targets better early-stage decisions before molecules enter the clinic.

floridatoday.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery platform operating across small molecules, biologics, and synthetic biology with its own pipeline and Pharma.AI platform — directly comparable to Ainnocence's three-pillar AI platform model.

TypeDirect peer
Description

AI-enabled drug discovery combining high-throughput biology with machine learning across multiple therapeutic areas — competes for the same enterprise pharma AI discovery budget as Ainnocence.

TypeDirect peer
Description

Physics-based and AI/ML molecular simulation platform (LiveDesign) used by major pharma for small molecule discovery — directly competes with Ainnocence's CarbonAI chemistry pillar.

4Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed AI drug discovery spin-out leveraging DeepMind's AlphaFold — directly competes in AI biologics design where Ainnocence's sequence-first approach positions as a structural-data-independent alternative.

TypeDirect peer
Description

AI-driven small molecule discovery platform with multiple pharma partnerships and an internal pipeline — comparable business model targeting the same enterprise pharma customers as CarbonAI.

TypeDirect peer
Description

AI small-molecule design platform using structure-based and convolutional neural networks — competes head-to-head with Ainnocence's CarbonAI in virtual screening and lead generation.

TypeDirect peer
Description

AI + quantum physics drug discovery platform serving pharma across small molecules and crystal prediction — overlaps with both Ainnocence's CarbonAI chemistry and MaterialAI materials pillars.

TypeEmerging player
Description

AI platform for protein engineering and biologics design focused on sequence-based generative models — directly comparable to Ainnocence's SentinusAI antibody/protein design capabilities.

TypeEmerging player
Description

AI-driven drug discovery combining physics and ML for small molecule and biologics design — emerging competitor with overlap in both chemistry and biologics pillars of Ainnocence's platform.

TypeRegional player
Description

AI platform for materials and chemicals R&D — comparable to Ainnocence's MaterialAI in serving semiconductor, chemical, and battery customers, though focused on industrial vs pharmaceutical materials.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ainnocence

AI Drug Discovery Platformainnocence.com

Ainnocence is an AI-native biotech developing sequence-based foundation models for biologics, small-molecule, and materials discovery, serving pharma, biotech, cosmetics, and semiconductor customers via platform licensing, fee-for-service, and co-development partnerships.

What Ainnocence does

Ainnocence is a California-based AI-native biotech founded in 2021 that develops sequence-based AI platforms for drug discovery and materials design. The company's core technology is a proprietary computationally efficient foundation model using block-circulant FFT layers and κ→1 Hessian conditioning, achieving 3.8× parameter reduction while powering three product pillars: SentinusAI® (biologics — antibodies, proteins, peptides, RNA, cell therapy, and synthetic biology), CarbonAI® (chemistry — small molecules, PROTACs, natural products, formulation, and cosmetic actives), and MaterialAI™ (advanced materials for semiconductors, alloys, and aerospace). The platform screens 10 billion+ compounds per day on a single GPU without requiring experimental 3D protein structures, claiming 10–60% wet-lab hit rates versus the 0.1–1% industry baseline and 80% cost reduction versus traditional high-throughput screening. Validation comes from peer-reviewed Nature Scientific Reports publication (2025), an ACS/C&EN white paper (2025), and 20+ PCT patents.

The company operates a multi-modal revenue model: (1) platform subscription licensing of its AI engines to pharma, biotech, CROs, cosmetics, and materials companies; (2) fee-for-service design campaigns where Ainnocence delivers wet-lab-ready lead candidates on a per-program or milestone basis; (3) co-development and strategic partnerships (exemplified by the January 2026 Phase Advance collaboration) with milestone payments and potential downstream royalties; and (4) B2B SaaS for cosmetics and materials R&D. Go-to-market combines enterprise field sales with consulting-style discovery, a self-service portal at app.ainnocence.com for mid-market adoption, scientific publication-driven inbound, and the JP Morgan Healthcare Conference as a key deal-closing venue. The company reports 1–10 employees across Mountain View HQ and Boston, with no disclosed funding rounds to date, and is led by Founder/CEO Dr. Lurong Pan (ex-Bill & Melinda Gates Foundation Senior Investigator).

Ainnocence firmographics

Firmographics
Name
Ainnocence
Legal name
Ainnocence Inc.
Website
https://ainnocence.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Ainnocence is an AI-native biotech developing sequence-based foundation models for biologics, small-molecule, and materials discovery, serving pharma, biotech, cosmetics, and semiconductor customers via platform licensing, fee-for-service, and co-development partnerships.
Ownership category
akta.pro rank

Ainnocence industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Therapeutic antibody design
  • Small molecule discovery
  • Materials science AI
  • Computational biology

Where Ainnocence is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Ainnocence business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Platform Licensing: Ainnocence licenses its AI platforms (SentinusAI, CarbonAI, MaterialAI, etc.) to pharmaceutical, biotech, and materials companies. This is the primary revenue model, targeting enterprise customers through annual or multi-year subscription contracts.
  2. Fee-for-Service (FFS) Design Campaigns: Per-project or per-campaign design engagements where Ainnocence applies its AI platforms to specific therapeutic programs, delivering wet-lab-ready lead candidates. Charged on a per-program or milestone basis.
  3. Co-Development / Strategic Partnerships: Joint development arrangements with pharmaceutical partners where Ainnocence contributes AI-driven drug design capabilities, often tied to milestone payments and downstream royalties. The Phase Advance collaboration exemplifies this model.
  4. B2B SaaS for Beauty and Materials R&D: Platform subscriptions and usage-based access for cosmetic brands and materials companies (e.g., CosmeticAI for beauty R&D, MaterialAI for semiconductor and chemical companies), uncorrelated to pharmaceutical revenue streams.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualPlatform subscription and per-program pricing models available via app portal

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Ainnocence product offering

Product offering

Core offering

Ainnocence develops three AI-driven platform pillars for therapeutic and materials R&D: SentinusAI for biologics (antibodies, proteins, peptides, RNA, cell therapy, synthetic biology), CarbonAI for chemistry (de novo small molecules, natural products, synthesis planning, formulation, cosmetic actives), and MaterialAI for advanced materials (alloys, semiconductors, crystals). All three are powered by a proprietary computationally efficient foundation model using block-circulant FFT layers and operate on sequence representations rather than requiring experimental 3D protein structures. The platforms are licensed to pharma, biotech, CROs, cosmetics, and semiconductor customers via subscription, fee-for-service design campaigns, and co-development partnerships.

Product overview

Ainnocence operates a platform-plus-modules architecture organized around three core AI pillars: biologics, chemistry, and materials. The flagship biologics platform SentinusAI® (protein/antibody design engine) includes five integrated modules: Antibody Studio, Peptide Studio, RNA Studio, Cell Studio, and SynBio Studio. The chemistry platform CarbonAI® (small molecule design engine) integrates SynMagic™ for retrosynthesis planning alongside modules for natural products, synthesis, formulation, and cosmetic actives. MaterialAI™ provides a separate AI materials discovery pillar. All three platforms share a proprietary computationally efficient foundation model as the core technology engine. Additional products include SenseAI® (RNA therapeutics), BioSynthAI® (synthetic biology), FormulaAI® (formulation optimization), NatmolAI® (natural products), CellulaAI® (cell therapy), PeptideAI® (peptide design), and CosmeticAI® (cosmetic ingredients). The company was founded in 2021 in California and serves customers across big pharma, biotech, CROs, cosmetics, semiconductors, and chemicals sectors.

Differentiator

Problem solved

Functional benefit

Brands

  • SentinusAI: AI platform for de novo protein design and antibody engineering using deep learning to predict and optimize protein structures.
  • CarbonAI
  • CellulaAI
  • NatmolAI
  • PeptideAI
  • BioSynthAI
  • FormulaAI
  • MaterialAI
  • CosmeticAI
  • SenseAI
  • SynMagic

Products and services

  • SentinusAI® End-to-end AI platform for therapeutic antibody and biologics discovery operating on protein and DNA sequence data. Built on a proprietary up-to-1-billion-parameter transformer-based protein foundation model trained on 53.5M+ sequences and 4.04M+ antibody screening datapoints. Achieves 85.7% affinity maturation success across 42 antibody projects and 10–60% wet-lab hit rates versus an industry baseline of 0.1–1%. Includes Product Modules: Antibody Studio (IgG, Fab, scFv, VHH design and affinity maturation), Peptide Studio (cyclic, stapled, GLP-1 analogs), RNA Studio (mRNA codon optimization, siRNA design), Cell Studio (cell line engineering, genome screening), and SynBio Studio (gene design, strain optimization). Sold via platform subscription, fee-for-service design campaigns, and co-development licensing to biopharma, biotech, peptide, RNA therapeutics, and cell therapy customers.
  • CarbonAI® End-to-end molecular chemistry platform for de novo small-molecule and PROTAC drug design and discovery, trained on a 2.02B-entry chemical foundation model with 600K molecular generation, 564K target binding, and 267,872 ADMET datapoints. Capabilities include virtual screening of up to 10 billion compounds within hours, scaffold hopping, multi-objective optimization, and the SynMagic retrosynthesis planning module with 95% synthesis success rate. Includes Product Modules: Molecule Design, Natural Products (800K+ NP database and TCM modernization), Synthesis Planner, Formulation Engine, and Cosmetic Actives. Sold to pharma, biotech, CROs, specialty chemicals, and cosmetics customers via subscription licensing and fee-for-service design campaigns.
  • MaterialAI™ AI-based platform for advanced materials discovery and optimization, operating on 9.04M material entries across six categories including 1.4M experimental crystals, 5.475M DFT-relaxed inorganics, 1.3M catalyst surfaces, 33K superconductor entries, 700K organic/organometallic entries, and 132K ML benchmark splits. Capabilities include alloy and composite design (high-performance alloys, functional materials, nanomaterials), semiconductor materials (polyimide FCCL, TPU elastomers, process optimization), and crystal structure prediction (stability, phase prediction, process routes). Sold to semiconductor manufacturers, chemical companies (BASF, Dow, DuPont), battery, and aerospace customers via platform licensing and project-based consulting, with revenue uncorrelated to the pharmaceutical pillars.
  • Fee-for-Service Design Campaigns Per-program or per-campaign design engagements in which Ainnocence applies SentinusAI, CarbonAI, MaterialAI, and related modules to specific therapeutic or materials programs, delivering wet-lab-ready lead candidates. Billed on a per-program or per-milestone basis with milestones tied to design, screening, and validation outcomes. Targets pharma, biotech, CRO, and specialty chemical customers that need expert execution on a specific program rather than a platform license.
  • Co-Development Strategic Partnerships Joint development arrangements with pharmaceutical and clinical partners in which Ainnocence contributes AI-driven drug design capabilities and the partner contributes development, clinical, or commercial capabilities. Structured with milestone payments and downstream royalties. The Phase Advance collaboration is the flagship example, integrating Ainnocence's AI-driven drug design with predictive clinical outcome modeling to reduce development timelines by over 50%.

Quantifiable outcome

  • Up to 80% reduction in early drug discovery cost and time
  • +7 more outcomes

Companies that use Ainnocence

Customer profile

Segments5 records

Ideal customer profiles5 records

Ainnocence technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature10 records

Ainnocence partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Phase AdvancecoreStrategic or Co-development Partner · 29 January 2026Industry-first AI collaboration integrating Ainnocence's AI-driven drug design capabilities with Phase Advance's predictive clinical outcome modeling. The partnership aims to reduce drug development timelines by over 50% and lower clinical trial failure rates. Addresses critical failure points where approximately 95% of drug candidates fail before preclinical research and 98% fail Phase 1 trials. The collaboration was finalized at the JP Morgan Healthcare Conference and targets better early-stage decisions before molecules enter the clinic.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Ainnocence competitors and assessment

Company assessment

Direct peers

  • Insilico Medicine: AI-driven drug discovery platform operating across small molecules, biologics, and synthetic biology with its own pipeline and Pharma.AI platform — directly comparable to Ainnocence's three-pillar AI platform model.
  • Recursion Pharmaceuticals: AI-enabled drug discovery combining high-throughput biology with machine learning across multiple therapeutic areas — competes for the same enterprise pharma AI discovery budget as Ainnocence.
  • Schrödinger, Inc. Physics-based and AI/ML molecular simulation platform (LiveDesign) used by major pharma for small molecule discovery — directly competes with Ainnocence's CarbonAI chemistry pillar.
  • Isomorphic Labs: Alphabet-backed AI drug discovery spin-out leveraging DeepMind's AlphaFold — directly competes in AI biologics design where Ainnocence's sequence-first approach positions as a structural-data-independent alternative.
  • Exscientia: AI-driven small molecule discovery platform with multiple pharma partnerships and an internal pipeline — comparable business model targeting the same enterprise pharma customers as CarbonAI.
  • Atomwise: AI small-molecule design platform using structure-based and convolutional neural networks — competes head-to-head with Ainnocence's CarbonAI in virtual screening and lead generation.
  • XtalPi: AI + quantum physics drug discovery platform serving pharma across small molecules and crystal prediction — overlaps with both Ainnocence's CarbonAI chemistry and MaterialAI materials pillars.

Emerging players

  • Cradle: AI platform for protein engineering and biologics design focused on sequence-based generative models — directly comparable to Ainnocence's SentinusAI antibody/protein design capabilities.
  • Iambic: AI-driven drug discovery combining physics and ML for small molecule and biologics design — emerging competitor with overlap in both chemistry and biologics pillars of Ainnocence's platform.

Regional players

  • Citrine Informatics: AI platform for materials and chemicals R&D — comparable to Ainnocence's MaterialAI in serving semiconductor, chemical, and battery customers, though focused on industrial vs pharmaceutical materials.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ainnocence social profiles

Digital presence

Ainnocence financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ainnocence leadership team

Management profile

Number of profiles

Profiles11 records

Ainnocence funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ainnocence M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ainnocence

What does Ainnocence do?

Ainnocence develops three AI-driven platform pillars for therapeutic and materials R&D: SentinusAI for biologics (antibodies, proteins, peptides, RNA, cell therapy, synthetic biology), CarbonAI for chemistry (de novo small molecules, natural products, synthesis planning, formulation, cosmetic actives), and MaterialAI for advanced materials (alloys, semiconductors, crystals). All three are powered by a proprietary computationally efficient foundation model using block-circulant FFT layers and operate on sequence representations rather than requiring experimental 3D protein structures. The platforms are licensed to pharma, biotech, CROs, cosmetics, and semiconductor customers via subscription, fee-for-service design campaigns, and co-development partnerships.

Is Ainnocence a public or private company?

Ainnocence is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Ainnocence founded?

Ainnocence was founded in 2021. It employs 11 to 50 people.

Where is Ainnocence based?

Ainnocence is headquartered in Mountain View, United States, in the North America region.

How does Ainnocence make money?

Four revenue lines are on record. Platform Licensing is the primary driver. The others are fee-for-Service (FFS) Design Campaigns, co-Development / Strategic Partnerships and B2B SaaS for Beauty and Materials R&D.

Who are Ainnocence's main competitors?

Direct peers on record are Insilico Medicine, Recursion Pharmaceuticals, Schrödinger, Inc., Isomorphic Labs, Exscientia, Atomwise and XtalPi. Emerging players are Cradle and Iambic. Citrine Informatics is listed as a regional player.

Does Ainnocence have an API?

No public API is recorded for Ainnocence.

What industry is Ainnocence in?

Ainnocence's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceAINN-P1: Small Model, Big IntelligenceAinnocence Inc. announced AINN-P1, a sequence-first protein foundation model, which achieved a stability score of 0.625 on ProteinGym, 39% above a 100B-parameter model. It also outperformed ESM2-base on unseen antibody programs by 0.15 AUC with 3.9x fewer parameters.BioSpaceAinnocence Shows AINN-P1 Protein Foundation Model Improves Antibody-Antigen Affinity Ranking by 28% - From Sequence AloneAinnocence released research showing its AINN-P1 protein foundation model improves antibody-antigen affinity ranking by 28%, raising mean Spearman rank correlation from 0.42 to 0.53. The gain comes from sequence-only embeddings, with a linear probe outperforming a task-specific network. The company plans task-adaptive fine-tuning to widen the margin.BioSpaceAinnocence Reports 91.4% Program Success Rate Across 58 Antibody Affinity Maturation Campaigns, Opens 28-Program Biologics Pipeline to LicensingAinnocence reported a 91.4% success rate across 58 antibody affinity maturation campaigns, with 53 of 58 producing improved binders. The company is seeking licensing for 28 antibody, bispecific, and ADC programs with positive preclinical data. It also noted 9 of 17 de novo campaigns yielded validated hits.EIN PresswireAinnocence's AINN-P1 Demonstrates Efficient Protein Prediction and Antibody EngineeringAinnocence announced AINN-P1, a 167M-parameter protein foundation model using multiplicative LSTM, which outperformed larger models on protein stability and antibody expression. It achieved a stability score of 0.625 and exceeded ESM2 by 0.15 AUC on new antibody programs with 3.9x fewer parameters.EIN PresswireAinnocence Shows Its Protein Foundation Model Improves Antibody-Antigen Affinity Ranking by 28% - From Sequence AloneAinnocence released research showing its AINN-P1 protein foundation model improves antibody-antigen affinity ranking by 28% from sequence alone. The model raised mean Spearman rank correlation for ΔΔG from 0.42 to 0.53, with a linear probe on frozen embeddings outperforming a task-specific network. The company plans task-adaptive fine-tuning and wet-lab validation.EIN PresswireAinnocence Reports 91.4% Success Across 58 Antibody Affinity Maturation Campaigns, Opens 28-Program Biologics PipelineAinnocence reported 91.4% success across 58 antibody affinity maturation campaigns, with 53 of 58 improved binders. The company is seeking licensing for 28 antibody, bispecific, and ADC programs, including a TL1A×p40 bispecific and an anti-VEGF scFv-IgG. It also announced de novo design success rates of 7.5% and 30% on rounds one and two.BioSpaceAinnocence Brings Its Protein, Antibody, and Peptide AI Models to Production as Secure, On-Demand APIsAinnocence launched its protein, antibody, and peptide AI models as secure, on-demand APIs. The models include AINN-P1, AINN-Basemodel, and AINN-Peptide, with the peptide platform screening over 3.2 million variants at over 90% accuracy. The APIs return predictions in under a second and scale elastically with demand.EIN PresswireAinnocence Brings Its Protein, Antibody and Peptide AI Models to Production as Secure, On-Demand APIsAinnocence launched its protein, antibody, and peptide AI models as secure on-demand APIs, including AINN-P1, AINN-Basemodel, and AINN-Peptide. The peptide platform screened over 3.2 million variants at over 90% accuracy, and integration time was reduced from months to an afternoon.BioSpaceAinnocence Proposes a Seven-Rule Governance Framework and Value Scorecard for AI-Driven Drug DiscoveryAinnocence Inc. proposed a seven-rule governance framework and a two-dimensional value scorecard for AI-driven drug discovery. The rules address asymmetric error costs, biased training data, and diffuse responsibility, while the scorecard evaluates molecular output and energy efficiency. The company aims to adopt the framework as an early practitioner.EIN PresswireAinnocence PeptideAI Platform screens 3.2M peptides with 90%+ accuracy in activity and therapeutic property predictionsAinnocence announced validated benchmarks for its PeptideAI platform, which screened over 3.2 million peptide variants. The platform achieved 90.2% accuracy and 93.2% ROC-AUC for activity prediction, and 77.8% micro F1 for 13 therapeutic properties. The serverless GPU backend delivers predictions in under 50 milliseconds per query.